OQROGet OQRO Pro
Insider trade

Eli Lilly (LLY)10% owner sold ~$54.2M

LILLY ENDOWMENT INC, 10% owner at Eli Lilly, sold ~$54.2M of Eli Lilly shares.

~$54.2M
Approx. value · 64K sh @ $848.30
94.8M
Holds after · shares reported
Traded
Oct 6, 2025
Filed
Oct 7, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  2. Dec 11, 2024Congress · 2 peopleMembers of Congress: 2 purchases
  3. Apr 23, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  4. May 6, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  5. May 21, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  6. Jun 9, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  7. Jul 10, 2025Congress · 1 personMembers of Congress: 2 purchases
  8. Jul 16, 2025Congress · 1 personMembers of Congress: 2 sales
  9. Aug 8, 2025InsiderDirector purchased ~$128K of LLY shares in the open market
  10. Aug 11, 2025InsiderOfficer sold ~$784K of LLY shares in the open market
  11. Aug 11, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  12. Aug 12, 2025Insider · 4 peopleInsiders: 5 purchases (~$2.8M)
  13. Aug 13, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.1M)
  14. Aug 14, 2025Congress · 2 peopleMembers of Congress: 2 purchases, 1 sale
  15. Aug 15, 2025InsiderCFO purchased ~$495K of LLY shares in the open market
  16. Aug 22, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  17. Aug 28, 2025InsiderOfficer sold ~$735K of LLY shares in the open market
  18. Sep 18, 2025Insider · 1 personInsiders: 5 sales (~$81.5M)
  19. Sep 19, 2025Insider · 1 personInsiders: 2 sales (~$18.1M)
  20. Sep 25, 2025FDAFDA drug approval: Inluriyo
  21. Oct 1, 2025Insider · 1 personInsiders: 46 sales (~$246.5M)

What came next

  1. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  2. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
  3. Oct 30, 20255% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 10.1%
  4. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
  5. Nov 20, 2025FDAFDA drug approval: Retevmo
  6. Nov 20, 2025FDAFDA drug approval: Retevmo
  7. Dec 19, 2025FDAFDA drug approval: Mounjaro
  8. Jan 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.8%
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by LILLY ENDOWMENT INC, 10% owner

The full history of LILLY ENDOWMENT INC, 10% owner is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data